Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

129.46 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Analyst Ratings for Blueprint Medicines ↗

January 23, 2023

Via Benzinga

Blueprint Medicines's Return On Capital Employed Overview ↗

November 07, 2022

According to data from Benzinga Pro, during Q3, Blueprint Medicines's (NASDAQ:BPMC) reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16...

Via Benzinga

Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake ↗

November 02, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗

November 02, 2022

Upgrades

Via Benzinga

9 Analysts Have This to Say About Blueprint Medicines ↗

November 02, 2022

Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:

Via Benzinga

Recap: Blueprint Medicines Q3 Earnings ↗

November 01, 2022

Blueprint Medicines (NASDAQ:BPMC) reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Where Blueprint Medicines Stands With Analysts ↗

September 09, 2022

Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Where Blueprint Medicines Stands With Analysts ↗

December 12, 2022

Via Benzinga

Blueprint Medicines' Ayvakit 'Will Garner Approval' Despite Questions, This Analyst Says ↗

August 18, 2022

Via Benzinga

Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday ↗

November 02, 2022

Needham raised Uber Technologies, Inc. (NYSE: UBER) price target from $52 to $54. Needham analyst Bernie McTernan maintained the stock with a Buy rating. Uber shares fell 0.3% to $29.65 in pre-market...

Via Benzinga

NASDAQ:BPMC Investor Notice: Investigation over Potential Wrongdoing at Blueprint Medicines Corporation ↗

October 12, 2022

San Diego, CA -- (SBWIRE) -- 10/12/2022 -- Certain directors of Blueprint Medicines Corporation are under investigation over potential breaches of fiduciary duties.

Via SBWire

Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022 ↗

September 14, 2022

Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low...

Via Benzinga

Analyst Sees Deteriorated Treatment Effect Of Blueprint's Much Awaited Mastocytosis Data ↗

August 17, 2022

Via Benzinga

Data From Blueprint Medicines' Blood Disorder Trial Fails To Lift Shares ↗

August 17, 2022

Blueprint Medicines Corporation (NASDAQ: BPMC)

Via Benzinga

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC

September 05, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Blueprint Medicines Corporation (NASDAQ:BPMC) Investor Notice: Investigation over Possible Violations of Securities Laws ↗

August 30, 2022

San Diego, CA -- (SBWIRE) -- 08/30/2022 -- Blueprint Medicines Corporation is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

What 14 Analyst Ratings Have To Say About Blueprint Medicines ↗

August 22, 2022

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:

Via Benzinga

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

August 19, 2022

From The Schall Law Firm

Via Business Wire

Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday ↗

August 22, 2022

Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday.

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

August 18, 2022

From The Schall Law Firm

Via Business Wire

This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday ↗

August 18, 2022

Gainers

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 17, 2022

Via Benzinga

EQUITY ALERT: Rosen Law Firm Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation – BPMC

August 17, 2022

From Rosen Law Firm

Via Business Wire

Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday ↗

August 17, 2022

Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split.

Via Benzinga

U.S. Stocks Open Lower; Nasdaq Down 150 Points ↗

August 17, 2022

U.S. stocks traded lower this morning, with the Nasdaq composite dropping more than 150 points on Wednesday.

Via Benzinga

Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session ↗

August 17, 2022

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus...

Via Benzinga

Blueprint Medicines Stock Is Getting Hammered Wednesday: What's Happening? ↗

August 17, 2022

Blueprint Medicines Corp (NASDAQ: BPMC) shares are trading lower by 22.2% to $53.32 Wednesday morning after the company announced top-line results from the registrational Part 2 of the PIONEER clinical...

Via Benzinga

Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint ↗

August 17, 2022

Blueprint Medicines met all its goals, but the results paled from an earlier study.

Via Investor's Business Daily

Blueprint Medicines Shares Fall After Topline Results From Late-Stage Neoplastic Disorder Study ↗

August 17, 2022

Blueprint Medicines (NASDAQ: BPMC) announced positive top-line results from the Part 2 of PIONEER clinical trial of AYVAKIT (avapritinib) in patients with non-advanced systemic mastocytosis (SM).

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.